Ocuphire Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid–In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2021 | 18,845,828 | $2 | $111,588 | $(89,368) | $22,222 |
| Issuance of common stock in connection with the at-the-market program | 1,848,980 | — | 4,428 | — | 4,428 |
| Issuance costs | — | — | (133) | — | (133) |
| Exercise of Series B warrants | 60,832 | — | — | — | — |
| Stock-based compensation | 81,366 | — | 1,807 | — | 1,807 |
| Exercise of stock options | 24,309 | — | 27 | — | 27 |
| Net and comprehensive income | — | — | — | 17,888 | 17,888 |
| Balance at December 31, 2022 | 20,861,315 | 2 | 117,717 | (71,480) | 46,239 |
| Issuance of common stock in connection with the at-the-market program and purchase agreement | 2,964,238 | — | 10,249 | — | 10,249 |
| Issuance costs | — | — | (136) | — | (136) |
| Exercise of Series B warrants | 17,869 | — | — | — | — |
| Stock-based compensation | 106,600 | — | 3,510 | — | 3,510 |
| Exercise of stock options | 27,469 | — | 30 | — | 30 |
| Net and comprehensive loss | — | — | — | (9,986) | (9,986) |
| Balance at December 31, 2023 | 23,977,491 | $2 | $131,370 | $(81,466) | $49,906 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.